Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 16/20 | 0.58 |
| ▸ | HTR2A | P28223 | 10/20 | 0.58 |
| ▸ | HTR1A | P08908 | 9/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826012 | 0.99 | DRD3 (0.63) | DRD3DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL826225 | 0.94 | DRD3 (0.65) | DRD3DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL1055026 | 0.92 | DRD3 (0.60) | DRD3DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL1056737 | 0.92 | DRD3 (0.60) | DRD3DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL12930984 | 0.92 | DRD3 (0.60) | DRD3DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL12930983 | 0.92 | DRD3 (0.61) | DRD3DRD2HTR2AHTR1A | |
| SCHEMBL9979373 | 0.91 | DRD3 (0.62) | DRD3DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL12073725 | 0.90 | DRD3 (0.61) | DRD3DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL18597149 | 0.89 | DRD3 (0.62) | DRD3DRD2HTR2AHTR1A | |
| SCHEMBL12930982 | 0.89 | DRD3 (0.62) | DRD3DRD2HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2017-07-13 | — | — | US | disclosed |
| US-9585965-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-07 | — | — | US | disclosed |
| US-9585965-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-07 | — | — | US | disclosed |
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2015-11-12 | — | — | US | disclosed |
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2015-11-12 | — | — | US | disclosed |
| US-9072788-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-07-07 | — | — | US | disclosed |
| US-9072788-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-07-07 | — | — | US | disclosed |
| WO-2011163594-A2 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | DRD3 4499/4885DRD2 4503/4885HTR2A 3774/4885 |
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | DRD3 4499/4885DRD2 4503/4885HTR2A 3774/4885 |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | PHPT1, SI, CA6 | DRD3 4499/4885DRD2 4503/4885HTR2A 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.